<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidermal growth factor receptor (EGFR) is highly expressed in colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and, as a result, it leads to the activation of downstream mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) kinase pathways for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> growth and progression </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical and preclinical studies, however, have shown that inhibition of epidermal growth factor receptor (EGFR) and mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) alone is not sufficient to treat colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In search of effective combination therapies, we show here that simultaneous targeting of EGFR with its inhibitor, <z:chebi fb="0" ids="114785">erlotinib</z:chebi> and mTOR with its inhibitor, <z:chebi fb="0" ids="9168">rapamycin</z:chebi> inhibits the phosphorylation and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the inhibition of cell cycle progression and the growth of both KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> and mutated colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells </plain></SENT>
<SENT sid="3" pm="."><plain>This study has demonstrated the principle that the combination of <z:chebi fb="0" ids="114785">erlotinib</z:chebi> and <z:chebi fb="0" ids="9168">rapamycin</z:chebi> may provide an effective therapy for colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
</text></document>